-
PublishedAugust 9, 2022
Insulin price cap championed by Collins stripped from spending bill by fellow Republicans
Sens. Susan Collins and Angus King both have sought to cap the drug's price, which has shot up tenfold in the U.S. – but not other countries - in 20 years.
-
PublishedJune 29, 2022
Federal task force to crack down on overprescription of opioids in the region
Four additional federal prosecutors will help local and federal law enforcement bring criminal cases against doctors and medical providers who are diverting opiates for profit.
-
PublishedApril 23, 2022
Maine Voices: Older Mainers deserve relief from high prescription drug costs
Congress has the power to get to the very heart of the problem – out-of-control drug prices – and right this wrong.
-
PublishedApril 12, 2022
Maine Voices: Unfair copay tactic allows health insurers to double-dip
L.D. 1783 will ensure that all Maine patients can afford their lifesaving medications.
-
PublishedApril 1, 2022
U.S. House passes $35-a-month insulin cap as Democrats seek wider bill
For the legislation to pass Congress, 10 Republican senators would have to vote in favor.
-
PublishedMarch 20, 2022
Our View: Maine lab shows drug companies how to fail
MDI Biological Laboratory is making drug discovery more efficient, saving time and money.
-
PublishedFebruary 14, 2022
Bill aims to lower the cost of the most expensive prescription drugs for Mainers
The bill would ensure that Mainers pay no more for prescription medications than their Canadian neighbors.
-
PublishedFebruary 10, 2022
Biden puts focus on prescription drug prices in fight against inflation
President Biden is trying to jump-start progress on his stalled domestic agenda by refocusing attention on one of his most popular proposals, limiting the cost of prescription drugs.
-
PublishedNovember 10, 2021
Maine Voices: There is a state-level solution to high prescription drug costs
Other states have passed laws regulating pharmacy reimbursements. Why not Maine?
-
PublishedNovember 9, 2021
Oklahoma court overturns $465 million opioid ruling against Johnson & Johnson
The Oklahoma Supreme Court weighed whether the company’s marketing and sale of opioids created a public nuisance.
Prescription drugs
advertisement